CN109985031A - The application for the drug that pulegone inhibits Escherichia coli biofilm to be formed in preparation - Google Patents
The application for the drug that pulegone inhibits Escherichia coli biofilm to be formed in preparation Download PDFInfo
- Publication number
- CN109985031A CN109985031A CN201910219373.0A CN201910219373A CN109985031A CN 109985031 A CN109985031 A CN 109985031A CN 201910219373 A CN201910219373 A CN 201910219373A CN 109985031 A CN109985031 A CN 109985031A
- Authority
- CN
- China
- Prior art keywords
- pulegone
- escherichia coli
- pga
- gene
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to pulegone applied technical fields, are a kind of applications of drug that pulegone inhibits Escherichia coli biofilm to be formed in preparation.The first public pulegone of the present invention has the function of inhibiting Escherichia coli biofilm formation, its expression by inhibiting the key controlling gene synthesized with Escherichia coli biofilm, to inhibit the formation of Escherichia coli biofilm, to reduce the resistance levels of Escherichia coli, the treatment for the resistance management and infectious diseases of the membrane-mediated Escherichia coli of biology provides new way.
Description
Technical field
It is that a kind of pulegone is raw in preparation inhibition Escherichia coli the present invention relates to pulegone applied technical field
The application for the drug that object film is formed；It further include pga A gene Huo ∕ and the pga B that pulegone inhibits Escherichia coli in preparation
The application of the drug of gene Huo ∕ and pga C gene Huo ∕ and pga D gene Huo ∕ and luxS gene expression and pulegone
In the application of preparation Escherichia coli biofilm medicament-resistant inhibitor.
Background technique
Escherichia coli as common clinical pathogenic bacteria, cause severe diarrhea, cholecystitis, peritonitis, cystitis, bacteremia,
Septicemia etc..Escherichia coli are also easy to produce beta-lactamase, it can hydrolyzing penicillin class, cephalosporins and monocycle class antibiotic
Beta-lactamase, so as to cause drug resistance.
Escherichia coli can not only attach to medical device (such as self retaining catheter, endotracheal intubation etc.) and form biomembrane correlation
Chronic infection, but also can in Urothelial Cell shape biomembrane, cause the infection of the urinary tract duration.As bacterium
Infection mechanism is primarily present form, the relatively free shape of the resistance levels (drug resistance) of the bacterial antibiotic under biofilm states
State improves 103Times or more.This makes biomembrane clinically be easier to cause intractable chronic infection, has seriously threatened the mankind's
Health.
The gene delivery occurred in bacterial biof iotalm is the main path that bacterium obtains drug resistant gene, and with biomembrane
Dissociation, the bacterial strain for obtaining drug resistant gene will lead to sending out for bacterial drug resistance, causes bigger harm.Studies have shown that forming life
Object film is that the important guarantee condition transmitted between bacterium occurs for drug resistant gene, therefore the Control factors that can influence biofilm formation must
To there is adjustment effect to the antibiotic resistance gene transfer occurred in biomembrane.The formation regulation of bacterial biof iotalm does not illustrate yet, has sent out
Existing major regulatory factor be density induction system activation after adjust biomembrane formation, wherein luxS and pga operon be compared with
Two important adjusting genes, luxS are that coliform densities induction system experiences molecule (autoinducer, AI) N- second certainly
The encoding gene of acyl serine lactone synzyme.It is secreted into Escherichia coli N- acetyl serine lactone and extracellular reaches a certain concentration
When, ATP binding cassette transporter for transporting sub (luxS-regulated (Lsr) transporter) can be adjusted by luxS
(ATP-binding cassette (ABC) transporter) is activated after being transferred into phosphorylation intracellular, with receptor knot
It closes, the expression of mediating effect+6 gene, plays and adjust the important physiology effect such as the sticking of bacterium, the formation of biomembrane and space structure
It answers.Pga operon is the coding base that Escherichia coli constitute biomembrane main component β -1,6-N- acetyl-D- dextran amine synzyme
Cause, the missing of pga gene can significantly affect the formation of bacterium initially sticked with biomembrane.
Summary of the invention
It is first the present invention provides a kind of application for the drug that pulegone inhibits Escherichia coli biofilm to be formed in preparation
The expression for the key controlling gene that secondary open pulegone is synthesized by inhibition with Escherichia coli biofilm, to inhibit large intestine bar
Bacterium biofilm formation, so that the resistance levels of Escherichia coli are reduced, resistance management and sense for the membrane-mediated Escherichia coli of biology
The treatment of infectious diseases provides new way.
Technical solution of the present invention first is that being realized by following measures: a kind of pulegone inhibits big in preparation
The application of the drug of enterobacteria biofilm formation.
Here is further optimization or/and improvement of one of the above technical solutions of the invention:
Above-mentioned pulegone comes from wrinkled giant hyssop.
Technical solution of the present invention second is that being realized by following measures: a kind of pulegone inhibits big in preparation
Pga A gene Huo ∕ and pga 1 B gene Huo ∕ and pga C gene Huo ∕ and pga D gene Huo ∕ and the luxS gene expression of enterobacteria
Drug application.
Here is further optimization or/and improvement of the technical scheme ii of the invention:
Above-mentioned pulegone comes from wrinkled giant hyssop.
Technical solution of the present invention third is that being realized by following measures: a kind of pulegone is preparing large intestine bar
The application of bacterium biomembrane medicament-resistant inhibitor.
Here is three further optimization and/or improvements to invention technology described above scheme:
Above-mentioned pulegone comes from wrinkled giant hyssop.
The first public pulegone of the present invention has the function of inhibiting Escherichia coli biofilm formation, by inhibiting and
Escherichia coli biofilm forms key regulatory genes (pga A, pga B, pga C, pga D, luxS) expression, to inhibit large intestine bar
Bacterium biofilm formation, so that the resistance levels of Escherichia coli are reduced, resistance management and sense for the membrane-mediated Escherichia coli of biology
The treatment of infectious diseases provides new way.
Detailed description of the invention
Attached drawing 1-1 is 16s RNA amplification curve.
Attached drawing 1-2 is 16s RNA solubility curve.
Attached drawing 2-1 is the amplification curve of tested bacterium pga A.
Attached drawing 2-2 is the solubility curve of tested bacterium pga A.
Attached drawing 3-1 is the amplification curve of tested bacterium pga B.
Attached drawing 3-2 is the solubility curve of tested bacterium pga B.
Attached drawing 4-1 is the amplification curve of tested bacterium pga C.
Attached drawing 4-2 is the solubility curve of tested bacterium pga C.
Attached drawing 5-1 is the amplification curve of tested bacterium pga D.
Attached drawing 5-2 is the solubility curve of tested bacterium pga D.
Attached drawing 6-1 is the amplification curve of tested bacterium luxS.
Attached drawing 6-2 is the solubility curve of tested bacterium luxS.
Attached drawing 7 is the tested bacterium mRNA expression variation histogram of pulegone patients before and after intervention.
Specific embodiment
The present invention is not limited by the following examples, can determine according to the technique and scheme of the present invention with actual conditions specific
Embodiment.It is previously mentioned various chemical reagent and chemical article in the present invention unless otherwise specified, is public in the prior art
Know common chemical reagent and chemical article；Room temperature, room temperature in the present invention refer generally to 15 DEG C to 25 DEG C of temperature, general to define
It is 25 DEG C.
The present invention will be further described below with reference to examples:
Embodiment 1: the application for the drug that pulegone inhibits Escherichia coli biofilm to be formed in preparation.
Pulegone English name in the present invention is (R)-(+)-pulegone, CAS No. 89-92-7.
Embodiment 2: pulegone inhibits pga A gene Huo ∕ and pga 1 B gene the Huo ∕ and pga of Escherichia coli in preparation
The application of the drug of C gene Huo ∕ and pga D gene Huo ∕ and luxS gene expression.
Embodiment 3: application of the pulegone in preparation Escherichia coli biofilm medicament-resistant inhibitor.
Embodiment 4: as the optimization of above-described embodiment, pulegone comes from wrinkled giant hyssop.
The present invention detects pulegium using real-time fluorescence quantitative PCR (Quantitative Real-time PCR) respectively
Ketone is to the major regulatory base for producing five kinds of the pga A of ESBLs Escherichia coli, pga B, pga C, pga D and luxS biofilm formations
The expression of cause, and pass through Expression (2-△△Ct) method progress relative quantification, analyze gene transcription level and life in tested bacterium
The correlation that object envelope is formed.
Experimental section: the detection (Quantitative Real-time PCR) of real-time fluorescence quantitative PCR
Tested bacterium single bacterium colony is inoculated in the fresh LB liquid medium for containing 5 % glucose, quiet in 37 DEG C of constant incubators
24 h of culture are set, the bacterium solution of biomembrane is formed, supernatant is abandoned in centrifugation, is chosen precipitating and is extracted according to RNA extracts kit specification
RNA, after detecting RNA concentration and purity with protein nucleic acid concentration mensuration instrument, reverse transcription cDNA.The method of qRT-PCR is examined
Cls gene expression.Using 16s as internal reference, with qRT-PCR primer amplification pgaA, pgaB, pgaC, pgaD, luxS gene, with not
Intervention group is the relative expression quantity that control calculates purpose detection gene after pharmaceutical intervention.The intervention concentration of pulegone is to inhibit
The MIC value that Escherichia coli biofilm is formed, 11.84 ug/ml.
The extraction of one RNA
3000 rpm of liquid medium of tested bacterium is centrifuged 10 min, is digested with 1ml TRLZOL and 1.5 ml centrifugation is added
Guan Zhong mixes, is placed at room temperature for 15 min.
The chloroform of 200 μ l is added, 5 min are placed at room temperature for after being mixed by inversion.
DEG C, 12000 rpm are centrifuged 15 min.
Supernatant is drawn into another new centrifuge tube, isometric isopropanol is added and mixes, -20 DEG C are placed 35
min。
DEG C, 12000 rpm are centrifuged 15 min, carefully outwell supernatant.
The ethyl alcohol of 75 % is added, precipitating is made to float washing.4 DEG C, 12000 rpm are centrifuged 15 min, carefully fall
Fall supernatant.
It is primary to repeat step 6.Blank pipe centrifugation, exhausts liquid.
Precipitating is dissolved with the water of RNase free.
Nucleic acid-protein quantitative instrument detects RNA concentration, and agarose electrophoresis detects RNA integrality.
Remaining RNA is placed in -80 DEG C of preservations or directly reverse transcription is used for subsequent experimental at the first chain cDNA.
2 first chain cDNA synthesis
It is prepared according to 1 reaction system of table.
It mixes gently, 25 DEG C of reaction 10 min, 42 DEG C of reaction 30 min, 85 DEG C of 5 s of reaction take out, and it is real to terminate reverse transcription
It tests.
The cDNA that reverse transcription is obtained is placed in -80 DEG C of preservations, and the sample cDNA of subsequent fluorogenic quantitative detection is used
RNase-free Water is reacted according to the dilution proportion of 1:1.
The experiment of three fluorescent quantitations
Fluorescent quantitation primer information
Strain: Escherichia coli str. K-12 substr. MG1655
Gene complete sequence ID:NC_000913 in NCBI
Method: using Primer 5.0, designs for this strain pga A, pga B, pga C, pga D and luxS gene order
QRT-PCR primer.Fluorogenic quantitative detection primer information is shown in Table 2.
Quantitative fluorescent PCR reaction system is shown in Table 3.
3. quantitative fluorescent PCR reaction condition is shown in Table 4.
Four experimental results
Quantify the solubility curve and amplification curve such as Fig. 1-1 to 6-2 of PCR.
Experiment detects the tested bacterium life of pulegone patients before and after intervention using Quantitative Real-Time PCR respectively
The expression of gene in object envelope, and pass through Expression (2-△△Ct) method progress relative quantification, it analyzes gene in tested bacterium and turns
The horizontal correlation formed with biofilm of record, the variation of the controlling gene of pharmaceutical intervention front and back biofilm formation.
The tested bacterium Quantitative RT-PCR of pulegone patients before and after intervention the results are shown in Table 5.
Pulegone pharmaceutical intervention front and back is compared to mesh using paired-sample t test (Paired-Sample T Test)
Gene influence, according to the data statistics result of table 5:
Impact analysis of the pulegone patients before and after intervention to target gene:
1. influence of the pulegone patients before and after intervention to pga A gene
With paired t-test, t=7.769, v=5, P=0.016(bilateral), difference has significant, it is believed that pulegone is dry
The expression quantity of pre- front and back pga A gene lowers (mean of patients before and after intervention difference is 0.5067).95% credibility interval of difference
0.2261-0.7873, does not include 0, equally illustrates that difference has significant.
2. influence of the pulegone patients before and after intervention to pgaB gene
Paired t-test, t=7.881, v=5, P=0.016(bilateral), difference has significant, it is believed that pulegone intervention
The expression quantity of front and back pgaB gene lowers (mean of patients before and after intervention difference is 0.3973).95% credibility interval 0.1804- of difference
0.6143, do not include 0, equally illustrates that difference has significant.
3. influence of the pulegone patients before and after intervention to pgaC gene
Paired t-test, t=14.311, v=5, P=0.005(bilateral), difference has significant, it is believed that pulegone is dry
The expression quantity of pre- front and back pgaC gene lowers (mean of patients before and after intervention difference is 0.4607).95% credibility interval of difference
0.3222-0.5992, does not include 0, equally illustrates that difference has significant.
4. influence of the pulegone patients before and after intervention to pgaD gene
Paired t-test, t=11.505, v=5, P=0.007(bilateral), difference has significant, it is believed that pulegone is dry
The expression quantity of pre- front and back pgaD gene lowers (mean of patients before and after intervention difference is 0.4953).95% credibility interval of difference
0.3101-0.6806, does not include 0, equally illustrates that difference has significant
5. influence of the pulegone patients before and after intervention to luxS gene
Paired t-test, t=9.026, v=5, P=0.0012(bilateral), difference has significant, it is believed that pulegone is dry
The expression quantity of pre- front and back luxS gene lowers (mean of patients before and after intervention difference is 0.4689).95% credibility interval of difference
0.2454-0.6926, does not include 0, equally illustrates that difference has significant.
The expression difference that sum up data analysis can obtain pulegone patients before and after intervention target gene has significant,
Expression quantity variation size sequence is successively: pga A, pga D, luxS, pga C, pga B.
Fig. 7 is shown in the tested bacterium mRNA expression variation of pulegone patients before and after intervention.
As seen in Figure 7, pulegone intervene Escherichia coli before and after pga A, pga B, pga C, pga D,
The mRNA expression difference of luxS has significant, shows as lowering, illustrates that pulegone affects pga and luxS
The expression of gene can be used as potentially to inhibit the formation of biomembrane for the drug resistant Chinese medicine medicament-resistant inhibitor of biomembrane.
In conclusion the first public pulegone of the present invention has the function of inhibiting Escherichia coli biofilm formation,
By inhibiting to form relevant adjusting gene (pga A, pga D, luxS, pga C, pga B) expression to Escherichia coli biofilm,
To inhibit Escherichia coli biofilm to be formed, so that the resistance levels of Escherichia coli are reduced, for the membrane-mediated Escherichia coli of biology
The treatment of resistance management and infectious diseases provides new way.
The above technical features constitute embodiments of the present invention, can basis with stronger adaptability and implementation result
Actual needs increases and decreases non-essential technical characteristic, to meet the needs of different situations.
Claims (6)
1. the application for the drug that pulegone inhibits Escherichia coli biofilm to be formed in preparation.
2. the application for the drug that pulegone according to claim 1 inhibits Escherichia coli biofilm to be formed in preparation,
It is characterized in that pulegone comes from wrinkled giant hyssop.
3. the pga A gene Huo ∕ and pga 1 B gene Huo ∕ and pga C gene Huo ∕ that pulegone inhibits Escherichia coli in preparation
With the application of the drug of pga D gene Huo ∕ and luxS gene expression.
4. pga A gene Huo ∕ and pga the B base that pulegone according to claim 3 inhibits Escherichia coli in preparation
The application of the drug of Yin Huo ∕ and pga C gene Huo ∕ and pga D gene Huo ∕ and luxS gene expression, it is characterised in that come into leaves thin
Lotus ketone comes from wrinkled giant hyssop.
5. pulegone is in the application of preparation Escherichia coli biofilm medicament-resistant inhibitor.
6. pulegone according to claim 5 is in the application of preparation Escherichia coli biofilm medicament-resistant inhibitor, spy
Sign is pulegone from wrinkled giant hyssop.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910219373.0A CN109985031A (en) | 2019-03-21 | 2019-03-21 | The application for the drug that pulegone inhibits Escherichia coli biofilm to be formed in preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910219373.0A CN109985031A (en) | 2019-03-21 | 2019-03-21 | The application for the drug that pulegone inhibits Escherichia coli biofilm to be formed in preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109985031A true CN109985031A (en) | 2019-07-09 |
Family
ID=67129097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910219373.0A Pending CN109985031A (en) | 2019-03-21 | 2019-03-21 | The application for the drug that pulegone inhibits Escherichia coli biofilm to be formed in preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109985031A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011092655A2 (en) * | 2010-02-01 | 2011-08-04 | Università Degli Studi Di Roma "La Sapienza" | Mentha suaveolens essential oil and therapeutic activities thereof |
| CN106138197A (en) * | 2016-07-14 | 2016-11-23 | 新疆医科大学 | Herba Agastaches Rugosae volatile oil application in suppression antibiotic-resistance E. coli growth |
-
2019
- 2019-03-21 CN CN201910219373.0A patent/CN109985031A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011092655A2 (en) * | 2010-02-01 | 2011-08-04 | Università Degli Studi Di Roma "La Sapienza" | Mentha suaveolens essential oil and therapeutic activities thereof |
| CN106138197A (en) * | 2016-07-14 | 2016-11-23 | 新疆医科大学 | Herba Agastaches Rugosae volatile oil application in suppression antibiotic-resistance E. coli growth |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Raivio | Everything old is new again: an update on current research on the Cpx envelope stress response | |
| Belas et al. | Regulation of lateral flagella gene transcription in Vibrio parahaemolyticus | |
| Murata et al. | PhoPQ-mediated regulation produces a more robust permeability barrier in the outer membrane of Salmonella enterica serovar typhimurium | |
| Inoue et al. | Genome-wide screening of genes required for swarming motility in Escherichia coli K-12 | |
| Bagge et al. | Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and β-lactamase and alginate production | |
| Fabich et al. | Comparison of carbon nutrition for pathogenic and commensal Escherichia coli strains in the mouse intestine | |
| Li et al. | Quorum sensing in Escherichia coli is signaled by AI-2/LsrR: effects on small RNA and biofilm architecture | |
| Hennequin et al. | oxyR, a LysR-type regulator involved in Klebsiella pneumoniae mucosal and abiotic colonization | |
| Gore et al. | CsrA and Cra influence Shigella flexneri pathogenesis | |
| US20100184624A1 (en) | Arrays and methods comprising m. smithii gene products | |
| Pérez et al. | Diarrheagenic Escherichia coli in children from Costa Rica | |
| Tang et al. | Transcriptomic analysis of the adaptation of Listeria monocytogenes to growth on vacuum-packed cold smoked salmon | |
| Kajfasz et al. | Manganese uptake, mediated by SloABC and MntH, is essential for the fitness of Streptococcus mutans | |
| Li et al. | Global effects of catecholamines on Actinobacillus pleuropneumoniae gene expression | |
| Gerken et al. | Roles of the EnvZ/OmpR two-component system and porins in iron acquisition in Escherichia coli | |
| Lim et al. | Dimethyl sulfoxide and ethanol elicit increased amyloid biogenesis and amyloid-integrated biofilm formation in Escherichia coli | |
| Powers et al. | The Mla pathway in Acinetobacter baumannii has no demonstrable role in anterograde lipid transport | |
| Cordonnier et al. | Enterohemorrhagic Escherichia coli pathogenesis: role of long polar fimbriae in Peyer’s patches interactions | |
| Bo Andersen et al. | Oxygen restriction increases the infective potential of Listeria monocytogenes in vitro in Caco-2 cells and in vivo in guinea pigs | |
| Antunes et al. | Repression of Salmonella enterica phoP expression by small molecules from physiological bile | |
| CN109985031A (en) | The application for the drug that pulegone inhibits Escherichia coli biofilm to be formed in preparation | |
| Nove et al. | The role of efflux pumps and environmental pH in bacterial multidrug resistance | |
| Xu et al. | The KbvR regulator contributes to capsule production, outer membrane protein biosynthesis, antiphagocytosis, and virulence in Klebsiella pneumoniae | |
| Yoshino et al. | Stepwise evolution of a Klebsiella pneumoniae clone within a host leading to increased multidrug resistance | |
| Zuberi et al. | CRISPR interference (CRISPRi) mediated suppression of OmpR gene in E. coli: an alternative approach to inhibit biofilm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |